SAN DIEGO and TOKYO, Oct. 1, 2025 — Kura Oncology and Kyowa Kirin have announced the first patient dosing in a new cohort of the KOMET-007 Phase 1/2 clinical trial, evaluating ziftomenib, an oral menin inhibitor, in combination with quizartinib and standard chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) harboring FLT3 and NPM1 co-mutations. This trial represents a key step in addressing a subset of AML with poor prognosis and limited durable treatment options.
Science Significance
FLT3 mutations occur in about 30% of newly diagnosed AML and up to 50% of NPM1-mutated AML cases, driving aggressive disease biology and higher relapse rates. Preclinical studies demonstrate that ziftomenib synergizes with FLT3 inhibitors like quizartinib to enhance antileukemic activity without additional toxicity. The KOMET-007 study is designed to evaluate safety, tolerability, and remission rates, aiming to establish a new combination approach against high-risk AML.
Regulatory Significance
Ziftomenib has received FDA Breakthrough Therapy Designation for relapsed or refractory NPM1-mutated AML, underscoring regulatory recognition of its therapeutic potential. The new trial cohort expands ziftomenib’s footprint into frontline therapy settings, potentially laying the groundwork for future regulatory filings and label expansions if clinical outcomes remain strong.
Business Significance
Advertisement
By advancing ziftomenib into earlier lines of therapy, Kura Oncology and Kyowa Kirin are strengthening their positions in the global leukemia market. This collaboration could broaden commercial opportunities for both companies, particularly in AML—a market with high unmet need and strong demand for novel precision medicines. Positive data could also validate menin inhibition as a cornerstone therapy class in hematologic cancers.
Patients’ Significance
For patients with FLT3/NPM1 co-mutated AML, outcomes are historically poor, with high relapse rates and limited survival. The KOMET-007 trial offers hope for a new standard of care by integrating menin inhibition with targeted and intensive chemotherapy. If successful, this approach could provide patients with deeper, more durable remissions and better long-term survival prospects.
Policy Significance
The trial highlights the importance of policy frameworks that support accelerated clinical development of innovative therapies for high-risk cancers. By enabling collaborative international research and prioritizing orphan and breakthrough designations, health authorities can help ensure that patients with rare, aggressive cancers gain faster access to novel treatments.
The initiation of the KOMET-007 trial cohort combining ziftomenib with quizartinib and chemotherapy marks a critical advance in AML research. By bridging cutting-edge science with regulatory momentum and patient need, this study reinforces the potential of menin inhibition to reshape leukemia treatment and deliver meaningful clinical progress.
Source : Kura Oncology, Inc. Press Release
